Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company’s …
Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia® (ferric citrate) to its Medicare Part D …
Maxim analyst Jason McCarthy is out today with a new research note on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker reported fourth quarter …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its financial results for the fourth quarter and year ended December 31, 2016. The company also reviewed its commercial …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced presentation of additional data from its pivotal Phase 3 study for iron deficiency anemia (IDA) and non-dialysis dependent chronic …
FBR Capital analyst Christopher James weighed in with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker announced that the FDA granted approval for …
Keryx Biopharmaceuticals (NASDAQ:KERX) investors have a smile on their faces Wednesday, after the drug maker announced that the FDA has approved its application …
